GlassScriptPhysician profile
David M Campanelli
NPI 1790763829
$631.55
in general payments reported to CMS, 2019-2025
14 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.24 · 2020: $12.33 · 2022: $12.12 · 2023: $163 · 2024: $193 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $510.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $127.33 | 2023-2025 | |
| Abbvie INC. | $104.91 | 2019-2025 | |
| Lilly USA, LLC | $80.62 | 2019-2025 | Mounjaro, Zepbound |
| Alkermes, INC. | $62.56 | 2023-2025 | Vivitrol, Vivitrol |
| Merck Sharp & Dohme LLC | $47.11 | 2024-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Glaxosmithkline, LLC. | $44.96 | 2019-2025 | Shingrix, Arexvy, Flulaval Quadrivalent |
| Novavax INC | $37.86 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Novo Nordisk INC | $33.37 | 2020-2023 | |
| Teva Pharmaceuticals USA, INC. | $23.74 | 2023 | Austedo Xr |
| Abbott Laboratories | $16.60 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $14.76 | 2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $14.44 | 2024 | |
| Avanir Pharmaceuticals, INC. | $11.75 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Campanelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.